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In group or cluster-randomized trials (GRTs), matching is a technique that can be used to improve covariate
balance. When baseline data are available, we suggest a strategy that can be used to achieve the desired balance
between treatment and control groups across numerous potential confounding variables. This strategy minimizes
the overall within-pair Mahalanobis distance; and involves iteratively: 1) making pairs that minimize the dis
tance between pairs of clusters with respect to potentially confounding variables; 2) visually assessing the po
tential effects of these pairs and resulting possible randomizations; and 3) reweighting variables of selecting
weights to make pairs of clusters. In step 2, we plot the between-arm differences with a parallel-coordinates plot.
Investigators can compare plots of different weighting schemes to determine the one that best suits their needs
prior to the actual, final, randomization. We demonstrate application of the approach with the MupirocinIodophor Swap Out trial. A webapp is provided.

1. Introduction
Individually randomized trials with blinding are the most rigorous
way of determining whether a causal relation exists between an inter
vention and an outcome (e.g. Ref. [1]). However, for scientific and
practical design reasons some interventions must be delivered to groups
of subjects. Trials where groups are randomized are called
group-randomized or cluster-randomized trials (GRTs). Three reasons
for conducting a GRT are: (i) because implementation occurs at the
cluster level, (ii) to avoid treatment contamination between subjects
who are in contact with one another, and (iii) to measure intervention
effects among cluster members who do not themselves receive treatment
[2,3]. GRTs are “the gold standard when allocation of identifiable
groups is necessary” [4].
One challenge in GRTs is that there is typically a small number of
clusters. Many GRTs have fewer than 30 independent clusters to
randomize, and most have fewer than 200. Thus, even though each
cluster may have thousands of individuals [2], there may well be
concern about confounding. In contrast, in large individually random
ized trials investigators expect randomization to balance potential
confounders across each arm of the trial. The smaller number of ran
domizable cluster in GRTs makes imbalance a threat to the causal

interpretation of any observed treatment effect.
Several approaches to this problem have been proposed, including
minimization [5], constrained randomization [6,7], and matching or
stratification (see, e.g. Ref. [8]). Briefly, minimization can be seen as a
sequential assignment of each randomized cluster to each arm such that
the imbalance after the addition of that cluster is minimized. It is better
suited to studies in which clusters are accrued as they are randomized. In
cases where many clusters are assembled before randomization begins,
it is dependent on the initial cluster and can be nearly deterministic.
Covariate constrained randomization effectively enumerates all
possible treatment assignments and eliminates those that do not meet
with desired features of balance. Usually schemes that have less than
some maximum value of covariate difference are selected, and then one
is chosen at random. For each group to have equal probability of
assignment to each arm of the trial, half of the selected schemes should
have it in one arm, the other half in the other. Although this is not
impossible, it is unlikely. To some trialists, any deviation from an equal
probability of assignment to each arm will be unacceptable; in any case
it is unclear how to make principled decisions about how much inequity
in arm assignment probability is allowable.
Extensive simulations compared analyses of constrained randomi
zation, simple randomization, and the truth for both binary and
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continuous, normally distributed outcomes [9,10]. For continuous out
comes, they demonstrate that adjustments for covariates at the analysis
stage are important even after design based adjustments. An adjusted
F-test must be used, and permutation tests must account for the balanced
scheme, otherwise constrained randomization improves power while
maintaining type I error rates. For binary outcomes, prior knowledge
should drive careful selection of covariates used in constrained
randomization to maximize power and maintain type I error rates.
Other research shows that constrained randomization has smaller
total sum of squares distance than simple randomization, minimization,
matching, and stratification when all clusters are known in advance
[11].
In stratified randomization similar clusters are grouped together
prior to randomization, and randomization takes place within these
smaller groups. There is debate about the optimal sizes of these groups.
In particular, there is disagreement about the merits of matching, which
involves grouping 2 clusters together, vs. stratification, where more than
2 clusters are grouped [12].
If there are a small number of groups in a trial, stratification is most
useful when there are only a few covariates to balance. Otherwise, strata
of size 4 are said to have all the advantages of matching with none of the
drawbacks [13].
Many authors address the value of matching in GRTs in both the
design stage and in the analysis [2,3,8,12,14–20]. Murray argues that
“the choice of matching or stratification [of] factors is critical to the
success of the procedure” [8]. Others suggest that caution must be used
when matching a small number of clusters due to the decrease in power
[2,18–20]. Breaking the matches, i.e., ignoring the matching during data
analysis, addresses this [15], but perhaps only when there is a small
number of large clusters [17]. Breaking the matches may also increase
the type I error rate for analyses that are not the intervention effect [17].
Further drawbacks include difficulties in estimating the intracluster
correlation coefficient, an inability to test for homogenity of odds ratio,
and predictions that are restricted to cluster-level baseline risk factors
[17]. Another complication involves removal of a cluster due to protocol
violations [21].
Imai et al. develop an estimator that gives accurate standard errors
when matched pairs are used; ignoring the matching gives slightly
conservative standard errors [16]. However, in one trial “matching
actually led to a loss in statistical efficiency” [19,22]. Despite this
ongoing debate, few authors discuss how to match the clusters [7].
This article describes an extension of methods discussed previously
[14]. We suggest a method suitable for a priori matching using baseline
data. In section 2, we outline our method. In section 3, we show how it
was applied in a large cluster-randomized trial, the Mupirocin-Iodophor
Swap Out trial [23]. In section 4 we discuss the implications of our
approach.

V1 = (υ11 , υ12 , …, υ1n )
V2 = (υ21 , υ22 , …, υ2n )
⋮ = ⋮
Vm = (υm1 , υm2 , …, υmn )
where vij is the jth variable from cluster i: each Vi contains pertinent
variables from cluster i. From here, we compute the Mahalanobis dis
tance between two clusters. This is the generalized n-dimensional dis
tance across the variables; for two clusters a and b it is calculated as
n
m
m
∑
∑
∑
(vak − vbk )2
d(Va , Vb ) =
where s2k = m1
(vlk − v⋅k )2 and v⋅k = 1n
vik .
s2
k=1

k

l=1

i=1

Then we find the way of pairing the clusters that minimizes the
global Mahalanobis distance across all of the possible pairs of clusters.
This is a short way of describing a lengthy process: we pair cluster 1 with
cluster 2 and cluster 3 with cluster 4, and so forth. Then we calculate the
Mahalanobis distance between each of these pairs, and sum it. Then we
pair cluster 1 with cluster 3 and cluster 2 with cluster 4, and we continue
until we have the summed Mahalanobis distance for all of the possible
ways to pair the clusters. The set with the minimum sum is the best way
to match the clusters. This process can be done in the R statistical pro
gramming environment [25] using the nmatch function in the
designmatch package [26].
Once the matching is completed, we have pairs (C11 , C12 ), (C21 , C22 ),
⎞

⎛

..., ⎝Cm2 1 , Cm2 2 ⎠, where Cij is the jth cluster in the ith pair. The first match
in each pair will be randomized to either treatment or control, the sec
ond to the other arm. If cluster C11 is randomized to treatment, we
denote this as CT11 , and this implies CC12 , where the superscript indicates
either treatment (T) or control (C). Next, we find the per variable dif
ference between the two groups, averaged across the clusters in the trial:
⃒∑m
⃒
⃒ 2 T ∑m2 C ⃒
⃒ i=1 Cij −
i=1 Cij ⃒
dj =
m
2

for j = 1, 2, ..., n. This generates the vector D = (d1 , …, dn ) of the average
pairwise difference between the arms for each variable. When the trial is
complete, these differences are likely to be reported as evidence of the
balance achieved in the randomization.
We repeat this process of randomization R times and find Dr, the
vector of average differences between the two arms for the rth practice
randomization. For study designs with more than 2 arms, Dr can be
redefined as, for example, the standard deviation between the arms. To
visualize we draw a parallel coordinates plot where the jth axis plots the
difference between study arms for variable j. On the plot we include Dr
for all practice randomizations r = 1, 2, …, R, as shown in the Figures
below.
Upon review of the plot, we may find that the balance between the
arms is unacceptable for some variables. For example, the mean or
maximum distance between the arms may be too large. To accommodate
this possibility, we introduce “weights” S = (s1, s2, …, sn), which control
the strength of matching on each variable. We have

2. Methods
We suggest an approach to the complex topic of balancing random
ization in GRTs. We match the clusters on many variables, using a
“weighting” scheme to suggest which variables are most important.
Then we perform many practice or “false” randomizations to obtain a
distribution of the possible average arm differences that might be ob
tained when actual randomization occurs. Investigators assess these
distributions to determine if potential randomizations would result in
sufficiently balanced treatment assignments. If not, the weighting
scheme is adjusted and the process begins again. The details follow. Our
approach is the same of that proposed by Greevy and colleagues [24], of
which we were unaware until writing this manuscript. In our approach,
we facilitate weight selection through a novel visual approach for
assessing the potential randomization quality for a given set of weights.
The initial step involves prioritizing variables (1, 2, …, n) from
clusters (1, 2, …, m) to be randomized. We have

v*ij =

m
∏

vij sj
i=1

which we combine to form
)
(
V1* = v*11 , v*12 , …, v*1n
)
(
V2* = v*21 , v*22 , …, v*2n
⋮

= ⋮
)
(
Vm* = v*m1 , v*m2 , …, v*mn .
If sj > sj*, we are multiplying variable j by a larger value than variable
2
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j*, and this has the effect of increasing the distance between clusters for
variable j, relative to variable j*. Then, counter-intuitively, when we rerun the matching algorithm, we will get closer matches for variable j
than variable j*, because the Mahalanobis distance minimization will
minimize this larger distance on variable j. Similarly, as the weight sv for
some variable v approaches 0, the distance between any two clusters
with respect to variable v becomes very small, relative to the other
variables. If sv = 0, v is effectively not included in the matching at all – all
clusters are perfectly matched on that variable during the matching
process, and any two clusters make an equally good match on that
variable. After selecting the weights S and matching on V *, we again
repeatedly find the vector of between-arm differences for each variable
Dr and plot it.
The cost of a high weight for variable j in this process is that closer
matches for variable j may result in reduced closeness in another vari
able. If so, compromises must be made. Investigators can perform iter
ative selections of the weights S and arrive at a set of weights S that
generates a distribution of randomizations that best reflect the most
desired and tolerable differences in specific characteristics between
arms.

application, built using the Shiny package in R, which implements the
strategy described in section 2. The application accepted an Excel
spreadsheet as input. This enabled the investigators to quickly and easily
change the weights applied to each potential matching variable. The
application allowed the investigators to set the desirable maximum
between-arm differences for each variable as well as the relative
weights. We input tolerable maximum differences between study arms
as well as desirable ranges of differences for each variable and compared
many sets of variable weights until we found one that was suitable.
To begin, we show a version of this process using just three of the 16
variables; the actual randomization preparation is described below.
Fig. 1 demonstrates how preparation for randomization would proceed
using 1) attributable patient days per month, 2) Staphylococcus aureus
rate, and 3) MRSA rate. To read a parallel coordinates plot, trace a single
gray line from “Pt Days” to “S aur rate” to “MRSA rate”; this shows the
between-arm differences obtained from a single randomization. The
investigators agreed that the tolerable maximum absolute mean differ
ence between treatment and control arms for these variables were: 80
attributable patient days per month, 0.15 difference in Staphylococcus
aureus infection rates, and 0.15 difference in MRSA rates. These define
the top of our axis lines in each graph. The black line indicates the mean
value of all points on each axis. We can also use this value to help decide
whether the matching was acceptable. To be completely clear, this
process begins in the knowledge that none of the particular practice arm
assignments that resulted in these D values will be used in the actual
trial: these are hypothetical randomizations that might be applied to the
hospitals. In contrast, the pairs established with these weights are set by
the minimizing process and are fixed.
The graph on the left is a parallel coordinates plot displaying the
results of 300 randomizations when all the weights are equal, equivalent
to using the raw values of each variable. The number of possible ran
m
domizations for a given matching is 2 2 so more than 300 may need to be
assessed for an accurate representation. The values in the plot show that
several randomizations exceeded the desired maximum between-arm
difference in the second and third axis: there is a reasonable chance
that if randomization occurred with this weighting, the Staphylococcus
aureus and MRSA rates would be imbalanced between the treatment and
control arms. To rectify this, we should increase the weights sr for those
variables. In the center graph a weight of 8 has been applied to the
Staphylococcus aureus rate. In this graph, the matching of hospitals is
strongly adjusted so that hospitals with similar Staphylococcus aureus
rates are paired. This results in smaller mean difference between the
treatment and control arms for that variable. The values on the middle
axis are all well below the desired maximum value: if randomization
occurred using these strengths we are likely to get suitable balance in
this variable. Unfortunately, there is a penalty. Hospitals with similar
Staphylococcus aureus rates do not have similar attributable patient days
per month and MRSA rates, which results in a few of these values
exceeding the maximum tolerable difference between arms. In partic
ular, the chance of a trial randomization with a difference in MRSA rates
greater than 0.15 is too high with these weights. The right plot shows the
randomizations when the matching weights for each variable were 1, 4,
and 2, respectively. This plot shows all 300 randomizations comfortably
below the predetermined maximum mean arm differences.
In the actual study, we used this approach with all 16 variables listed
above. After trying many weights we chose a set of weights that
balanced the covariates between the two arms, as seen in Fig. 2. Weights
are recorded in the figure legend. For all the variables, none of these
randomizations resulted in intolerable between-arm differences, and for
most, the mean difference was much closer to 0 than the maximum
tolerable. When it was time to assign the hospitals to their interventions,
we used these weights to match hospitals in the study into pairs, then
formally randomized one member of each match to treatment and the
other to control. Note that some weights were 0; these variables were not
used in the matching, but the figure still helps to visualize the between-

3. Results
To demonstrate the usefulness of this technique we present a brief
summary of our randomization process using baseline data from the
Mupirocin-Iodophor
Swap
Out
trial
(www.clinicaltrials.gov,
NCT03140423) [23]. This trial follows the REDUCE MRSA trial [27] in
which universal use of mupirocin nasal swabs and daily bathing with
chlorhexidine was shown to markedly reduce methicillin resistant
Staphylococcus aureus (MRSA) clinical cultures and all-cause blood
stream infection in adult intensive care units (ICU) of hospitals
belonging to HCA Healthcare (HCA). One concern about the mupirocin
regimen is that S. aureus resistance to mupirocin is relatively common in
some communities and so the agent would be ineffective for many pa
tients. Another is that routine use of mupirocin, an antibiotic, may
provide selective pressure for resistant strains, thus rendering mupirocin
less effective for all uses. It would thus be desirable to be able to use a
substitute nasal component of the decolonizing regimen for which
resistance is less likely to be present or to develop as a result of treat
ment. The Swap Out trial is a cluster-randomized non-inferiority trial,
comparing the antibiotic mupirocin (the current standard of care) to the
antiseptic iodophor for nasal decolonization of ICU patients to assess
impact on Staphylococcus aureus clinical cultures and all-cause blood
stream infection during routine chlorhexidine bathing.
Baseline data collected from HCA’s centralized data warehouse were
available for matching prior to randomization. We used data from 20
months from 137 participating hospitals. Investigators prioritized 16
baseline variables into several categories. For this trial, the investigators
put the highest priority on baseline values of the primary outcome
measures, Staphylococcus aureus ICU-attributable clinical cultures per
1000 days, MRSA ICU-attributable cultures per 1000 days, and all
pathogen ICU-attributable bloodstream infections per 1000 days, as well
as average monthly attributable days, regional mupirocin resistance
estimates, percent of ICU admissions with a prior history of MRSA,
current usage of mupirocin (percent of mupirocin use in the first 5 days
of ICU admission), and current usage of chlorhexidine (percent adher
ence to daily chlorhexidine gluconate for bathing). Of secondary
importance were median ICU length of stay, and mean Elixhauser total
score [28]. Of tertiary importance were the percentage of ICU Medicaid
patients, and whether or not a facility uses polymerase chain reactions to
identify MRSA in blood. The next group included percent of admissions
involving a skilled nursing facility, and the percent of surgical admis
sions. The final group included whether the ICU had specialty units for
oncology, bone marrow transplant, or transplant units, and if the ICU
has bone marrow transplant or transplant units.
Prior to randomization, investigators used an interactive web-based
3
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Fig. 1. Possible randomizations for 3 different sets of weights for three attributes: average monthly attributable days (Pt days), Staphylococcus aureus ICU-attributable
cultures per 1000 days (S aur rate), MRSA ICU-attributable cultures per 1000 days (MRSA rate). Each light gray line represents a single randomization and the black
line is the mean difference between arms. The left image has no weighting and two axes exceed maximum values. The center image is matched well on the middle
axis, but the first and third have some randomization draws that would exceed the desired maximum values for the mean difference between the groups. The right
image reaches a happy medium.
Fig. 2. Weighting scheme used in the
Mupirocin-Iodophor Swap Out Trial.
The variables are: patient days (Pt days,
weight = 1), Staphylococcus aureus ICUattributable cultures per 1000 days (S
aur rate, weight = 4), MRSA ICUattributable cultures per 1000 days
(MRSA rate, weight = 2), all pathogen
ICU-attributable bloodstream infections
per 1000 days (All Blood, weight = 4),
regional mupirocin resistance estimates
(Mup R, weight = 2), percent of ICU
admissions with a prior history of MRSA
(Hx MRSA, weight = 1), baseline usage
of mupirocin (percent of mupirocin use
in the first 5 days of ICU admission (Mup
Adherence, weight = 1), current usage
of chlorhexidine (percent adherence to
daily chlorhexidine gluconate for bath
ing (CHG Adherence, weight = 1), me
dian ICU length of stay (Median LOS,
weight = 3), mean Elixhauser total score
(Comorbidity Score, weight = 1),
percent ICU patients insured by
Medicaid (Medicaid, weight = 0),
whether or not a facility uses polymer
ase chain reactions to identify MRSA in
blood (PCR Blood, weight = 0), percent
admissions involving a skilled nursing
facility (DC SNF), percent surgical ad
missions (Surgery, weight = 1), whether
the ICU had specialty units for oncology,
bone marrow transplant, or transplant
units (OncBMTTrp, weight = 2), if the ICU has bone marrow transplant or transplant units (BMTTrp, weight = 0). Note that Median LOS has the same value for all the
re-randomizations. That is, for this variable, every assignment of treatment and control within the pairs results in the same mean difference in median length of stay
between the control and treatment arms. This is likely due to the very small variability of this variable. The vast majority of the hospitals had the same median length
of stay.

arm differences obtained in the planning randomizations.

main differences are i) that we use a visualization method, the parallel
coordinates plot, to help investigators assess the effects of different
weighting schemes and that ii) we emphasize and clarify that weighting
must be an iterative and collaborative process. We also show a study
where the method was applied, as opposed to a hypothetical example. In
addition to the ongoing Swap Out trial shown in the Results section [23],
we also used the method in a recently completed and published trial [27,
29].
For general use, we recommend deciding on tolerable maximum
differences between study arms a priori and testing many combinations

4. Discussion
In this article, we discuss using an iterative process to 1) make pairs
that minimize the Mahalanobis distance between pairs of clusters with
respect to potentially confounding variables; 2) visually assessing the
potential effects these pairs and the resulting randomization; and 3)
reweighting variables by selecting weights to make pairs of clusters. This
process is similar to that proposed by Greevy and colleagues [24]. The
4
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of variable weights (S) until one is found which ensures that the eventual
randomization is likely to satisfy. We call this the Goldilocks Approach,
after the well-known fable, The Three Bears, in which Goldilocks tries
three bowls of porridge – one is too hot, another too cold, and the third is
just right [30]. More than three attempts to find a suitable combination
of variable weights may be needed.
Another advantage of the Goldilocks Approach is that many cova
riates can be accounted for in this method, and many more explored. We
also note that each cluster has equal probability of being assigned to
treatment or control, something that constrained randomization
forgoes.
It may bear reinforcement at this point that the many randomizations
performed in the Goldilocks Approach do not constitute a search for the
study randomization and treatment assignment with acceptable covar
iate balance. That description better suits the constrained randomization
approach described previously. In contrast, the treatment assignments
used in Goldilocks Approach are purely hypothetical. We should think of
them as addressing the question: “If we were to match with these
weights, what sort of covariate balance would we be likely to obtain in
our actual randomization?” After we have found the set of weights that
are just right, we formally randomize to assign the members of each
matched set to a study arm. We expect a covariate balance that is similar
to the ones seen in the parallel coordinates plot, but it is unlikely to be
identical to any of the ones seen.
While it is often possible to obtain satisfactory balance on many
covariates at the same time using the Goldilocks approach, there are
limits, of course. For example, we can effectively require perfect
matches on categorical variables by using large weights for them. If
some categories have few members, the matches on the remaining
variables are unlikely to be very close. For example if we place a large
weight on suburban vs. urban hospital location, and have only 8 urban
hospitals, we will be unlikely to find good matches on the other char
acteristics among those 8 hospitals.
The web-based application described above can be found at bit.ly/
GoldilocksApp, and an instructional video explaining the use is here bit.
ly/GoldilocksVid. We invite the community to use these resources,
which are still under development.
While the Goldilocks approach to trial randomization cannot ensure
balance between the treatment and control arms, it allows us as in
vestigators to explore different weighting schemes. Choosing weights
and assessing their likely impact means that the effects of matching and
balance for relevant potential confounders can be observed and
compared. Investigators who conduct GRTs and plan to match can use
this method prior to randomizing to help ensure balance between
treatment and control arms.
As our reviewers noted, we must also recommend caution when
matching in both the design phase and analysis phase of research.
Matching has consequences. It can result in reduced power and diffi
culties in calculating the intracluster correlation coefficient along with
the multitude of faults mentioned in the introduction. Take care.
While the Goldilocks approach to trial randomization cannot ensure
balance between the treatment and control arms, it allows us as in
vestigators to explore different weighting schemes. Choosing weights
and assessing their likely impact means that the effects of matching and
balance for relevant potential confounders can be observed and
compared. Investigators who conduct GRTs and plan to match can use
this method prior to randomizing to help ensure balance between
treatment and control arms.

Fund and administered by the National Institute of Allergy and Infec
tious Diseases (UH2/UH3 AT007769). The findings and conclusions
expressed in this article are those of the authors and do not necessarily
represent the official position of the National Institutes of Health or the
CDC.
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